Revised forecast
Fiscal year ending September 2026 · Second quarter (cumulative) and full yearPrevious forecast published 11 November 2025The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
The forecast for the cumulative second quarter was revised upward due to sales growth in the healthcare business and the DX support business for corporate customers, among others, an upside in operating profit and an increase in equity-method investment gains. The forecast for interim net income was also revised upward, primarily because ¥425 million will be deducted from income taxes, inhabitant taxes and enterprise taxes following the finalization of the loss on the sale of shares associated with the transfer of all shares in consolidated subsidiary VideoMarket, in addition to these factors. For the full year, forecasts for net sales, ordinary profit and net income were revised upward to reflect the upside in cumulative second-quarter net sales, ordinary profit and interim net income, while the operating profit forecast was maintained because expenses for developing systems for pharmacy DX and the cost burden related to “LunLun Mirai Support” are included in the plan.
Loss on the sale of shares associated with the transfer of all shares in consolidated subsidiary VideoMarket Co., Ltd. (finalized). Amount: Not disclosed. The disclosure states that ¥425 million will be deducted from income taxes, inhabitant taxes and enterprise taxes.
| Item | Details |
|---|---|
| Net Sales | Second quarter (cumulative): 15,000 / Full year: 31,000 → Second quarter (cumulative): 15,666 / Full year: 31,500（Second quarter (cumulative): +4.4% / Full year: +1.6%） |
| Operating profit | Second quarter (cumulative): 1,400–1,600 / Full year: 3,100–3,500 → Second quarter (cumulative): 1,679 / Full year: 3,100–3,500（Second quarter (cumulative): +5.0–+20.0% / Full year: −） |
| Ordinary income | Second quarter (cumulative): 1,450–1,650 / Full year: 3,100–3,500 → Second quarter (cumulative): 2,063 / Full year: 3,400–3,800（Second quarter (cumulative): +25.1–+42.3% / Full year: +8.6–+9.7%） |
| Profit attributable to owners of the parent | Second quarter (cumulative; interim net income): 780–920 / Full year: 1,770–2,050 → Second quarter (cumulative; interim net income): 1,863 / Full year: 2,560–2,840（Second quarter (cumulative): +102.6–+138.9% / Full year: +38.5–+44.6%） |
| Net income per share | Second quarter (cumulative; interim net income): 14.06–16.58 / Full year: 31.90–36.95 → Second quarter (cumulative; interim net income): 33.58 / Full year: 44.29–49.33 |
| Fiscal Period Covered | Fiscal year ending September 2026 |
| Period Covered | Second quarter (cumulative) and full year |
| Publication date of previous forecast | 11 November 2025 |
| Previous-period results | Second quarter (cumulative): net sales ¥14,885 million, operating profit ¥1,639 million, ordinary profit ¥1,721 million, interim net income attributable to owners of the parent ¥1,757 million, interim net income per share ¥31.87 / Full year: net sales ¥29,910 million, operating profit ¥2,946 million, ordinary profit ¥3,027 million, net income attributable to owners of the parent ¥3,404 million, net income per share ¥61.62 |
| Reason for the revision | The forecast for the cumulative second quarter was revised upward due to sales growth in the healthcare business and the DX support business for corporate customers, among others, an upside in operating profit and an increase in equity-method investment gains. The forecast for interim net income was also revised upward, primarily because ¥425 million will be deducted from income taxes, inhabitant taxes and enterprise taxes following the finalization of the loss on the sale of shares associated with the transfer of all shares in consolidated subsidiary VideoMarket, in addition to these factors. For the full year, forecasts for net sales, ordinary profit and net income were revised upward to reflect the upside in cumulative second-quarter net sales, ordinary profit and interim net income, while the operating profit forecast was maintained because expenses for developing systems for pharmacy DX and the cost burden related to “LunLun Mirai Support” are included in the plan. |
| Details and amount of extraordinary loss | Loss on the sale of shares associated with the transfer of all shares in consolidated subsidiary VideoMarket Co., Ltd. (finalized). Amount: Not disclosed. The disclosure states that ¥425 million will be deducted from income taxes, inhabitant taxes and enterprise taxes. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Results for the cumulative second quarter are expected to exceed the previous forecast due to sales growth in the healthcare business and the DX support business for corporate customers, as well as an increase in equity-method investment gains. The main factor behind the upside in net income is expected to be a ¥425 million reduction in income taxes and other taxes resulting from the finalized loss on the sale of shares associated with the transfer of shares in consolidated subsidiary VideoMarket.